Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

Search

Top

Back to Contracts

EMBED 3.0 - Improvement of Formulations

Awarded

ocds-h6vhtk-078aeeInternational

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This contract, titled EMBED 3.0 - Improvement of Formulations, is a direct award between Cardiff University and ProMed Pharma, LLC, valued at 187,587 GBP excluding VAT. Funded by the B&M Gates Foundation, the project focuses on enhancing the viability of medication delivery technology developed during previous stages of the EMBED project. The primary objective is to refine additional batches and create a more robust mechanism for medication entry into patients, which is a critical requirement for the project to progress into the next phase, EMBED 4.0, involving human trials. The award was published on October 19, 2026, and was issued via a direct award under Regulation 41, Schedule 5, paragraph 2, following a review of previous work conducted by the EMBED research team and ProMed. This phase of development is essential for demonstrating the technical capability necessary to move from initial development to clinical application.

General Info

Cardiff University and ProMed Pharma contract for 187,587 GBP to improve medication delivery.

Agency

Cardiff University

Contract Value

$0

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

GBR

Set-Aside

NONE

Awardee

Documents

1

award

Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseAwarded

PostedOct 19

Award Notice

AwardedNov 5

Contract was awarded

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyCardiff University

Contacts1 person available

OfficeN/A

Organization / AgencyCardiff University

Office AddressN/A

Contacts

contact@example.gov

Full Description

Show more

The B&M Gates Foundation (funder) have reviewed the work with the EMBED research team, undertaken with the manufacturer ProMed, and have decided that to push the EMBED 3.0 project into its next stage (EMBED 4.0 – Human Trials), they’ll need to demonstrate their ability to vary the additional batches offer a more robust mechanism for the medications to enter patients. The additional work has been again funded by the foundation for the purpose of increasing the viability of the delivery method (technology developed as part of EMBED) - Previous direct award for the initial development via Regulation 41 - Schedule 5, para 2.

Similar Contracts

Same NAICS industry code

Immunohistochemical (IHC) Analysis SupportThe Immunohistochemical (IHC) Analysis Support subcontract, issued by the NASA Shared Services Center, involves providing specialized staining and chemical analysis of sectioned tissue for prime contractors on NASA Space Biosciences projects. The scope of work requires the application of antibodies and reagents to cryo-sectioned slides and the use of fluorescence microscopes and IHC staining stations to evaluate neuronal morphology. Due to the technical nature of the work, specialized training in neuro-histology is required to deliver the final analyzed slides and digital imaging reports. This opportunity is categorized under NAICS code 541714 and is associated with a performance location in zip code 94035. The solicitation was posted on November 4, 2026, with a response deadline of November 9, 2026.

NASA Shared Services Center

POSTED

about 21 hours ago

DEADLINE

Service request for specimen embedding and sectioning.

Solicitation # 80NSSC27948767Q

The NASA Shared Services Center is seeking custom histology research services to support a Space Biosciences Project evaluating neuronal morphology in mouse brains exposed to radiation, isolation, and simulated microgravity. The scope of work involves planning, preliminary testing, embedding, and cryo-sectioning of specific brain regions, including the substantia nigra, hippocampus, and prefrontal cortex. The contractor must provide slides with sections 15 microns thick, which are to be delivered to Principal Investigator Dr. Joshua Alwood within 90 days after receipt of order. Performance will be located at the NASA Ames Research Center. This procurement is being conducted under FAR Part 12 for commercial items and services, with the government intending to issue a sole source contract to ZYAGEN, identified as the sole provider of the required services. While the agency is currently requesting capability statements from interested organizations by November 9, 2026, to determine if a competitive procurement is feasible, it explicitly states that quotes will not be reviewed or accepted at this stage. Primary coordination for this effort is managed by Cara Craft and Will Garrett.

NASA Shared Services Center

POSTED

about 21 hours ago

DEADLINE

Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-014

The National Institutes of Health (NIH) issued solicitation RFA-AI-28-014 to establish centers focused on the systems-level understanding of the links between infectious pathogens, inflammatory pathways, and chronic diseases. The program supports two types of centers: Chronic and Infectious Diseases Systems Biology Centers (CIDSB), which examine the bidirectional link between chronic and infectious diseases, and Systems Biology Inflammation Centers (SBI), which focus on the role of inflammation in chronic diseases to identify precision medicine targets. The primary goals are to develop predictive computational models for disease progression, discover novel drug targets and biomarkers, and create harmonized, FAIR-compliant cross-disease datasets. The total program funding is 26 million dollars, with an expected 10 awards and an individual award ceiling of 2.5 million dollars. Applications must be submitted electronically via Grants.gov by February 18, 2027. The proposal structure is multi-component, requiring an overall section, an administrative core, a data and modeling core, and a biospecimen collection and processing core, with additional requirements for research projects and optional cores depending on the center type. Evaluation is based on an overall impact score focusing on significance and the qualifications of the investigators. Awardees must comply with strict cybersecurity incident reporting requirements, notifying the HHS awarding agency within 48 hours of discovery, and must adhere to rigorous biosafety and human subjects protection standards. Applicants must maintain active SAM registration and UEI identifiers to be eligible for funding.

National Institutes Of Health

POSTED

DEADLINE

In Vivo Efficacy and Toxicology StudiesThis subcontract, titled In Vivo Efficacy and Toxicology Studies, supports the National Institutes of Health and the Department of Health and Human Services by providing preclinical validation of biologic therapies for prime contractors on NIH/NINDS ADRD projects. The scope of work involves executing in vivo efficacy, safety pharmacology, and toxicology studies utilizing translationally appropriate animal models specifically for Alzheimer's and Frontotemporal Dementia. To fulfill the requirements, the contractor must utilize GLP-compliant toxicology lab facilities to ensure regulatory standards are met. The primary deliverables include comprehensive preclinical validation reports and detailed toxicology data packages necessary for Investigational New Drug submission. The project is categorized under NAICS code 541714, with a response deadline set for October 10, 2028.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

Genome Editing Construct and Delivery System OptimizationThis subcontract focuses on the design and optimization of genome editing constructs and biologic delivery systems to support prime contractors on NIH/NINDS genomic therapy projects. The scope of work involves utilizing CRISPR/Cas technology along with viral and non-viral vectors to refine editing constructs and delivery mechanisms. The selected provider will be responsible for assessing critical metrics including bioactivity, target engagement, durability, pharmacokinetics, and bioavailability. The final deliverables for this engagement consist of optimized therapeutic leads accompanied by comprehensive bioactivity and pharmacokinetics data reports.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

NCI Research Specialist (Clinician Scientist)The NCI Research Specialist subcontract involves providing leadership and implementation services for National Cancer Institute funded clinical trials on behalf of prime contractors. The selected clinician scientist will be responsible for writing and revising protocols for national cancer clinical trials, managing trials within a clinical trials office, and recruiting patients. Additionally, the role requires active participation in NCI scientific review, monitoring, and steering committees. Candidates must possess clinician scientist status and demonstrated experience in cancer clinical research. The contract requires a dedicated effort ranging from 2.4 to 4.8 person-months per year. This opportunity is associated with the National Institutes of Health under the Department of Health and Human Services, with a response deadline set for February 20, 2029.

National Institutes Of Health

POSTED

DEADLINE

in over 2 years

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Solicitation # RFA-NS-28-012

The National Institutes of Health, under the Department of Health and Human Services, has issued solicitation RFA-NS-28-012 to support the translation of genome editing and biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). This includes Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. The program funds the entire translational pipeline, from therapeutic lead optimization and drug product development to IND-enabling studies and early first-in-human clinical evaluations. Key activities include optimizing editing constructs and delivery systems, demonstrating in vivo efficacy, conducting safety pharmacology and toxicology studies, and developing scalable manufacturing processes that align with regulatory expectations. The agency intends to commit 6 million dollars in both fiscal years 2028 and 2029, with an expected three awards and a maximum project period of five years. Individual annual budget caps are set at 1.3 million dollars in direct costs, increasing to 2.5 million dollars for projects involving clinical trials. Awards are governed by the Public Health Service Act and federal regulations 42 CFR Part 52 and 2 CFR Part 200. Evaluation is based on an Overall Impact Score considering significance, innovation, approach, investigator expertise, and environment, with a specific focus on the Target Product Profile and the use of quantitative Go/No-Go milestones. Eligible applicants include small businesses and other for-profit organizations. Requirements for submission include active registration in the System for Award Management, a Unique Entity Identifier, and eRA Commons accounts. Awardees must adhere to strict cybersecurity incident reporting protocols, notifying the agency within 48 hours of discovery, and must register applicable clinical trials with ClinicalTrials.gov. The solicitation features multiple application cycles with deadlines extending through October 10, 2028, and earliest start dates ranging from December 2027 to July 2029.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Solicitation # PAR-28-042

Solicitation PAR-28-042, issued by the National Institutes of Health under the Department of Health and Human Services, is a funding opportunity designed to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer. The program focuses on tools for cancer detection, diagnosis, prognosis, monitoring, and the prediction of treatment response or toxicity. Funding is available through either a phased UH2/UH3 mechanism or a standalone UH3 mechanism to facilitate laboratory optimization and clinical validation using human samples. Key deliverables include the demonstration of assay results associated with clinical endpoints, the establishment of statistical cut-off values, and the definition of sensitivity and specificity. All clinical laboratories must adhere to CLIA, GLP, or ISO 17025 standards. Awards are determined via a peer review system based on an overall impact score, evaluating the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Specific evaluation criteria include the clarity of milestones for transitioning from UH2 to UH3 phases and the adequacy of commercialization plans. Eligible applicants include small businesses, for-profit organizations, higher education institutions, and 501(c)(3) nonprofits. Applicants must maintain active registrations in SAM.gov, eRA Commons, and Grants.gov. Additionally, recipients must comply with strict cybersecurity incident reporting requirements, notifying the agency within 48 hours of discovery, and ensure all human subject protocols are reviewed by an Institutional Review Board or Independent Ethics Committee.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

Specialized Bioscience Research & AnalysisThe Specialized Bioscience Research and Analysis subcontract, issued by the Biotechnology and Biological Sciences Research Council under UK Research and Innovation, focuses on advancing the understanding of living systems through curiosity-driven research. The selected provider will support prime contractors on bioscience discovery projects by performing advanced biological research, laboratory analysis, and experimental validation. Key technical requirements include the use of high-throughput sequencing and advanced microscopy, with a final delivery expectation of comprehensive experimental data and peer-reviewed publications. To qualify for this engagement, providers must possess PhD or Post-doc credentials and maintain valid institutional biosafety certifications. The project emphasizes team science methodologies to achieve its research goals. Interested parties must submit their responses by February 9, 2027, in accordance with the solicitation posted on November 3, 2026.

Biotechnology and Biological Sciences Research Council (BBSRC)

POSTED

DEADLINE

2026 to 2027 strategic Longer and Larger (sLoLa): full stage

Solicitation # 189488

The Biotechnology and Biological Sciences Research Council (BBSRC), under UK Research and Innovation (UKRI), is soliciting proposals for the 2026 to 2027 Strategic Longer and Larger (sLoLa) program. This initiative funds large-scale, team-based, curiosity-driven bioscience discovery research projects aimed at achieving major breakthroughs in the fundamental understanding of living systems. Eligible projects must utilize a fully integrated team science approach, demonstrate a need for extended and large-scale funding, and enhance the overall capability and capacity of UK biosciences. Projects can last up to five years, and the full economic cost must exceed 2 million pounds, with BBSRC providing 80 percent of that cost. The selection process is conducted in two stages. The outline stage opened on April 16, 2026, and closed on June 25, 2026, with evaluations based on vision, approach, and team capability. Successful outline applicants are invited to the full stage, which opened on November 5, 2026, and closed on February 9, 2027. Full proposals are evaluated via external peer review and a multidisciplinary panel, focusing on management strategy and strategic case. Final funding recommendations are made by the Strategic LoLa Committee following an interview process with the highest-rated teams. All applications are managed through the UKRI Funding Service.

Biotechnology and Biological Sciences Research Council (BBSRC)

POSTED

DEADLINE

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Solicitation # PAR-28-042

The National Cancer Institute, under the National Institutes of Health, has issued solicitation PAR-28-042 to provide funding for the analytical and clinical validation of biomarkers and assays related to cancer. This initiative focuses on molecular, cellular, and imaging markers used for detection, diagnosis, prognosis, treatment response, prevention, and toxicity monitoring. The goal is to support laboratory optimization and validation for assays using human samples that address specific clinical needs and intended uses. Eligible projects may utilize either a standalone UH3 mechanism or a phased UH2/UH3 approach, though clinical trials are explicitly not allowed. The solicitation was posted on November 3, 2026, with a response deadline set for November 17, 2029.

National Cancer Institute

POSTED

DEADLINE

in about 3 years

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Solicitation # RFA-NS-28-012

The National Institute of Neurological Disorders and Stroke, under the National Institutes of Health, has issued solicitation RFA-NS-28-012 to support the translation of genome editing and biologic therapies for Alzheimer's Disease-Related Dementias. This initiative covers a broad range of conditions, including Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. The program is designed to advance the translational pipeline from initial therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Eligible activities include the optimization of delivery systems and editing constructs, the assessment of bioactivity and pharmacokinetics, and the demonstration of in vivo efficacy. Additionally, the funding supports safety pharmacology, toxicology studies, and the creation of scalable manufacturing processes and quality attributes that meet regulatory standards. This solicitation was posted on November 3, 2026, with a response deadline of October 11, 2028.

National Institute Of Neurological Disorders And Stroke

POSTED

DEADLINE

in almost 2 years

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS